Biotech cleared to make biosimilar of $6bn treatment after landmark ruling

Regeneron and Bayer suffered a UK setback as the court followed others in Europe in its interpretation of the so-called SPC manufacturing waiver.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Sandoz wins Fed Circ reversal of $39m hair loss patent verdict

19 November 2025 The court rules that Duke University and Allergan’s patent lacked sufficient written description, in the wake of stricter post-Amgen Section 112 standards.

Americas

Latham steps into dispute over $6bn treatment, replacing Kirkland

13 August 2025 Firm takes over Novartis in major patent litigation | Move follows rival firm's withdrawal after conflict-of-interest challenge | Latham team led by new hire from Cravath.

More features

Ex-Teva counsel and FDA regulatory specialist returns to private practice

Use of genAI to draft patents ‘a big concern’: CIPA’s AI chair

What people talked about at London Life Sciences Week

NHS updates outdated IP rules in bid to revive UK life sciences

MSD wins full sweep in world’s best-selling drug clash

Report reveals surge of AI adoption in IP but lawyers remain cautious

INTA votes in new 2026 president at Florida leadership meeting

Sandoz wins Fed Circ reversal of $39m hair loss patent verdict

Biotech cleared to make biosimilar of $6bn treatment after landmark ruling

More on this story

Editor's picks

Editor's picks

More features